Send to

Choose Destination
See comment in PubMed Commons below
J Pediatr Hematol Oncol. 2007 Oct;29(10):678-87.

Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report.

Author information

  • 1Stem Cell Transplant Unit, Regina Margherita Children's Hospital, University of Turin, Piazza Polonia 94, 10126 Turin, Italy.

Erratum in

  • J Pediatr Hematol Oncol. 2008 Jan;30(1):115. Massimo, Berger [corrected to Berger, Massimo]; Rosanna, Pessolano [corrected to Pessolano, Rosanna]; Roberto, Albiani [corrected to Albiani, Roberto]; Sebastian, Asaftei [corrected to Asaftei, Sebastian]; Veronica, Barat [corrected to Barat, Veronica]; Francesca, Carraro [corrected to Carraro, Francesca]; Eleonora, Biasin [corrected to Biasin, Eleonara]; Enrico, Madon [corrected to Madon, Enrico]; Franca, Fagioli [corrected to Fagioli, Franca].


This study was aimed at ascertaining whether extracorporeal photopheresis (ECP) is an effective treatment for pediatric patients with steroid resistant graft versus host disease (GvHD). Fifteen patients with acute GvHD (aGvHD) and 10 patients with chronic GvHD (cGvHD) were enrolled in the study. At the start of the ECP protocol, aGvHD was staged as II (n=7), III (n=4), and IV (n=4). The response rate was 100% for aGvHD II, 75% for aGvHD III, and finally 0% for aGvHD IV (P=0.02). In multivariate analysis, the strongest predictor for ECP response was the aGvHD severity: aGvHD II 100%, aGvHD III-IV 30% [relative risk (RR) 5.071, confidence interval (CI) 95% 2.2-5.5, P=0.0016], this translates in a higher risk of transplant-related mortality for ECP nonresponders (RR 5.26, CI 95% 3.4-6.2, P=0.02). cGvHD was diagnosed as limited n=3, and extensive n=7; the response rate was 100% and 28% for limited or extensive cGvHD, respectively (P=0.03). For cGvHD the strongest predictor for ECP response was the absence of visceral organ involvement (RR 5.17, CI 95% 2-4.9, P=0.001), and the highest risk of transplant-related mortality was among patients not responding to ECP (RR 12.4, CI 95%, P=0.02). Our results suggest that ECP can rescue good-risk GvHD-patients, whereas for advanced, poor-risk GvHD patients, new therapies are required.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk